More than a century after insulin transformed type 1 diabetes from a fatal condition into a manageable disease, millions of people still struggle to access affordable, quality insulin and the monitoring facilities needed to use it safely.
More than a century after insulin transformed type 1 diabetes from a fatal condition into a manageable disease, millions of people still struggle to access affordable, quality insulin and the monitoring facilities needed to use it safely.
Highlighting this persistent gap, the World Health Organisation (WHO) has issued its first-ever guidelines for diagnosing and managing type 1 diabetes in adults, with a focus on making treatment accessible across healthcare settings, including those with limited resources.
Released around World Diabetes Day on November 14, the guidelines address a critical challenge in diabetes care: ensuring that people dependent on lifelong insulin therapy receive not just the medicine but also the support needed to manage their condition effectively.
An estimated 9.5 million people were living with type 1 diabetes globally in 2025, with another 5 lakh diagnosed during the year. Although the condition is commonly associated with childhood, it is increasingly being recognised in adults, underlining the need for better diagnosis and long-term care beyond paediatric services.
Unlike type 2 diabetes, type 1 diabetes occurs when the body produces little or no insulin, making patients dependent on daily insulin administration for survival. Any interruption in treatment can lead to serious complications, including life-threatening diabetic ketoacidosis.
The WHO recommends multiple daily insulin injections, with doses adjusted according to blood glucose levels. It recognises human insulin as an appropriate and effective treatment option, while allowing other insulin formulations when clinically required.
Regular blood glucose monitoring is another key recommendation. This can include finger-prick testing at home, continuous glucose monitoring through wearable sensors and periodic HbA1c tests at healthcare facilities to assess average blood sugar levels over the preceding months. Where blood glucose testing is unavailable, urine glucose testing may be considered.
“Insulin is a lifesaving treatment, discovered more than 100 years ago. Yet many people with type 1 diabetes do not have access to affordable and high-quality insulin,” said Dr Soren Brostrom, WHO Director of Noncommunicable Diseases and Mental Health.
The guidelines are intended to be applicable across healthcare settings, including emergency and humanitarian situations where medical services may be disrupted. They also support WHO's 2030 targets of ensuring that all people with type 1 diabetes have access to affordable insulin treatment and blood glucose self-monitoring.
For countries such as India, the recommendations bring into focus the need to make insulin therapy part of a wider continuum of care involving timely diagnosis, regular monitoring, patient education and medical supervision.
Simply prescribing insulin is not enough; patients and caregivers must also understand how to administer it correctly, monitor glucose levels and recognise warning signs of complications.
Dr Deepak Khadelwal, a diabetologist and endocrinologist from Paschim Vihar, Delhi, asserted that poor glucose control despite high insulin doses does not always mean that patients need more medication. Problems with injection technique, repeated use of the same injection sites, improper storage and underlying infections can all undermine treatment.
He cited the case of a patient of a kidney transplant who was taking 120-130 units of insulin daily but continued to have poor sugar control. On examination, doctors found severe thickening of the tissue in both calves, where the patient had repeatedly been injecting insulin. After shifting injections to appropriate sites and correcting the technique, the daily insulin requirement reportedly fell to 20-30 units, with blood sugar coming under control, Dr Khandelwal said at a two-day conference Diabcon 2026 organised recently by Delhi Diabetic Forum & Dept. of Medicine, Lady Hardinge Medical College (LHMC).
He explained that repeated injections into the same area can cause lipohypertrophy, a thickening of the fatty tissue beneath the skin that can interfere with insulin absorption and make glucose levels unpredictable. The case, he said, illustrates why doctors need to examine injection sites and administration techniques before simply increasing insulin doses.
Regular monitoring is another weak link in diabetes management. Patients may feel well despite persistently high blood sugar because the condition often progresses without obvious symptoms. Some continue taking the same medicines for months or even years without checking whether their treatment is working.
A sudden rise in blood sugar can also be an early indication of an infection that might otherwise go unnoticed.
Insulin storage is another concern, particularly during summer. “Exposure to excessive heat can compromise its effectiveness,” Dr Khandelwal said, stating that he often encounters patients whose glucose readings rise unexpectedly during hot weather and improve after their insulin supply is replaced.
Maintaining the recommended storage conditions and protecting insulin from excessive heat are therefore essential parts of treatment.
He added that when glucose remains uncontrolled despite apparently good adherence, doctors must also investigate lifestyle factors, missed medication, other drugs that may affect blood sugar and possible underlying conditions. These could include latent autoimmune diabetes in adults (LADA), pancreatic diabetes and hormonal disorders such as Cushing's syndrome and acromegaly, which may sometimes be mistaken for conventional type 2 diabetes.
WHO has also called for people living with type 1 diabetes to be actively involved in designing, implementing and evaluating national diabetes programmes, recognising that their experiences are essential to making healthcare more responsive.
Tags